STAT+: Hims Hers will stop selling compounded vers...

What’s Happening

Real talk: Hims Hers will stop selling what it claims to be a cheaper, compounded version of Novo Nordisk’s obesity pill on its telehealth platform.

Letters to the editor Letters to the editor STAT readers respond on the ethics of gender-affirming care for minors, the new food pyramid, and more By Torie Bosch First Opinion First Opinion As a scientist and NFL widow, I am furious about a recent NFL Players Association-funded CTE study By Eleanor M. Perfetto Pharmalot Pharmalot STAT Plus: HHS asks Justice Department to probe Hims & Hers over its cheaper compounded version of Wegovy By Ed Silverman A STAT Examination A STAT Examination STAT Plus: TrumpRx claims to offer the lowest prices. (shocking, we know)

But many drugs have cheaper generics By John Wilkerson , J.

Why This Matters

Emory Parker , Chelsea Cirruzzo , Elaine Chen , and Daniel Payne Politics Politics Scientists worry finalizing ‘Schedule F’ rule will further politicize NIH grant decisions By Anil Oza STAT Plus: Vertex’s CRISPR treatment for sickle cell disease hits unexpected roadblock By Jason Mast STAT Plus: A rival goes after Ocular Therapeutix on eve of pivotal readout on eye treatment By Adam Feuerstein STAT Plus: Trump administration officials blocked FDA effort to fast-track review of psychedelic treatment By Lizzy Lawrence , Elaine Chen , and Damian Garde STAT Plus: FDA Commissioner Marty Makary tries to soothe staff concerns over voucher program By Lizzy Lawrence STAT Plus: Nektar Therapeutics is trying to stage a comeback.

Health experts are weighing in on what this means for people.

The Bottom Line

This story is still developing, and we’ll keep you updated as more info drops.

What do you think about all this?